16 /100
LOW RISK
Score updated Jul 13, 2026

DAWN — Day One Biopharmaceuticals Inc Dilution Risk Tracker

Track DAWN dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track DAWN — Get alerts when the score changes →

As of July 13, 2026, Day One Biopharmaceuticals Inc (DAWN) has a DilutionWatch DilutionScore of 16/100, rated LOW dilution risk. Day One Biopharmaceuticals Inc has a market capitalization of $2.22B, 103.33M shares outstanding, 216 institutional holders tracked. Key dilution vectors include approximately 34 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
20
💰 Cash Runway
10
📊 Float Risk
20
⚠️ Warrant Exposure
15
🔄Convertible Debt—

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for DAWN.
🔔 Track DAWN — Get forecast alerts →

💹 Market Data

Market Cap$2.22B
Shares Outstanding103.33M
Float71.35M
Cash$441.11M
Debt$2.79M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 16.6% shares (2026Q1 vs prior)
216 institutional holders · 101.09M shares
#1 BlackRock, Inc. 7.04M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 6.72M shares
#3 GLAZER CAPITAL, LLC 4.68M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest6.58M
Days to Cover5.4
% of Float9.2%
FINRA data as of Apr 15, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Dec 31, 2024
Full SEC filing analysis available with free account →

📰 Recent News

No recent news

📋 What This Means for DAWN Shareholders

Day One Biopharmaceuticals Inc (DAWN) has a DilutionScore of 16/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 13, 2026.

DilutionWatch's EDGAR monitoring for DAWN shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for DAWN in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for DAWN alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track DAWN Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking DAWN — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

LBTYA LBTYK AER AIG BABA

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for DAWN
📊 DAWN FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 DAWN Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.